NAPNAP is pleased to offer additional opportunities to enhance your knowledge at our national conference thanks to support from corporate partners.
Free Non-CE Meal Events
All of these non-CE educational opportunities are sponsored by companies with a focus on children’s health. Pre-registration is not required. Sponsoring companies will admit attendees on a space available basis. Don’t miss out!
Wednesday, March 18 at 12:15-1:30 p.m.
Healing the Barrier Microbiome Science and Ceramide-Based Strategies for Managing Atopic Dermatitis
Dr. Whitney Casares, MD, MPH, FAAPÂ
Lunch and Presentation
Meeting Room 301-304
This Non-CE product theater lunch is sponsored by CeraVe® and La Roche-Posay.
Advancements in Rett Syndrome (RTT) Care
Dr. Suad Khalil
Lunch and Presentation
Meeting Room 319-321
This Non-CE product theater lunch is sponsored by Acadia Pharmaceuticals.
Thursday, March 19 at 8-9:30 a.m.
Xolair: A Therapeutic Option for IgE Mediated Food Allergy
Lauren Herlihy, DNP, APRN, CPNP
Breakfast and Presentation
Meeting Room 301-304
This Non-CE product theater breakfast is sponsored by Genentech, a member of the Roche Group.
Thursday, March 19 at 12:30-1:45 p.m.
Innovation in Action: The Impact of Cell-Based Influenza Vaccines
Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP
Lunch and Presentation
Meeting Room 301-304
This Non-CE product theater lunch is sponsored by CSL Seqirus.
From Awareness to Action: Elevating the Vaccine Conversation for IMD Prevention
Salisia Valentine, DNP, FNP-C, MSN, RN
Lunch and Presentation
Meeting Room 319-321
Invasive meningococcal disease (IMD) is uncommon, unpredictable, and can progress rapidly with serious consequences. This session provides a clear overview of IMD and the vaccines available to help prevent it, giving clinicians the essential information they need. The program also features a practical, skills focused segment on initiating and navigating meningococcal vaccine discussions, helping clinicians build confidence and effectiveness in guiding patients and caregivers.
This Non-CE product theater lunch is sponsored by GSK.
Friday, March 20 at 7:30-9 a.m.
Clinical Case Discussion: A Pediatric Patient With Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients
Douglas Kress, MD
Breakfast and Presentation
Meeting Room 301-304
Join us for a program discussing a real-world case of a pediatric patient with uncontrolled moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients.
This Non-CE product theater breakfast is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
Friday, March 20 at 11:40 a.m.-12:55 p.m.
Rethinking the Right Dose in ADHD Treatment: A Collaborative Discussion Between an NP and a Developmental and Behavioral Pediatrician
Gabriel Anzueto, MD and Sara Jones, PhD, APRN, PMHNP-BC, FAAN, FAANP
Lunch and Presentation
Meeting Room 301-304
This Non-CE product theater lunch is sponsored by Vertical Pharmaceuticals.
Inhibiting IL-4 and IL-13 Signaling Across Five Diseases Affecting Pediatric Patients
Jean Nelson, MS, FNP-C
Lunch and Presentation
Meeting Room 319-321
This Non-CE product theater lunch is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
Product Showcases
Product showcases will take place in Exhibit Hall C. No pre-registration is required.
Thursday, March 19
Discover a Treatment Option for Cholestatic Pruritus in Patients with Alagille Syndrome or PFIC
Dr. Shari Sheflin-Findling
1:15-1:45 p.m. – Exhibit Hall C
Light refreshments will be served.Â
This product showcase is sponsored by Ipsen Biopharmaceuticals.
Friday, March 20
Simplifying the Tween/Teen Skincare Conversation & Solutions for Early Onset Acne in Pediatric Patients
Sam Casselman, PNP
9-9:30 a.m. – Exhibit Hall C
Light refreshments will be served.Â
This product showcase is sponsored by CeraVe®.
Industry-sponsored Posters
All industry-sponsored posters will be displayed near the entrance of Exhibit Hall C during exhibit hours. Presenters will be available for questions on Wednesday, March 18 from 12:30-1:30 p.m. and 6-7 p.m. Note: CE credit will NOT be given for the industry-sponsored posters.
Poster #1: Understanding Impacts of Needle-free Epinephrine on Treatment Preference and Patient Quality of Life (QoL) in Food Allergic Pediatric Patients – Findings from a Discrete Choice Experiment Among Caregivers
Presented by: Joe Jones
Poster sponsored by: ARS Pharmaceutical Operations Inc.
Poster #2: Stability of epinephrine nasal spray under freeze, thaw, and extreme temperatures
Presented by: Joe Jones
Poster sponsored by: ARS Pharmaceutical Operations Inc.
Poster #3: Ease of use demonstrated in real world use of epinephrine nasal spray
Presented by: Tracy Wilson, DNP
Poster sponsored by: ARS Pharmaceutical Operations Inc.
Poster #4: Improvement in Atopic Dermatitis Signs and Symptoms With Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: the 52-Week Phase 3 INTEGUMENT-OLE Trial in ≥2-year-olds
Presented by: Anthony Russo
Poster sponsored by: Arcutis Biotherapeutics
Poster #5: Real-World Demographic, Clinical Characteristics, and Treatment Patterns among Males Treated with Trofinetide for Rett Syndrome
Presented by: Nazia Rashid
Poster sponsored by: Acadia Pharmaceuticals Inc.
Poster #6: Trofinetide for the Treatment of Rett Syndrome: Efficacy in Participants of the LAVENDER Study Who Had Dose Reductions
Presented by: Erin O’Connor Prange
Poster sponsored by:
Poster #7: Expert Consensus on Real-world Use of Trofinetide for Rett Syndrome: a Delphi Study
Presented by: Erin O’Connor Prange
Poster sponsored by: Acadia Pharmaceuticals Inc.
Poster #8: An Evaluation of Real-World Effectiveness and Safety of Trofinetide in Patients with Rett Syndrome: A Retrospective Chart Review
Presented by: Ryan Bucco
Poster sponsored by: Acadia Pharmaceuticals Inc.
Poster #9: Real-World Behavioral Improvements in Patients With Rett Syndrome Treated With Trofinetide: Interim Results of the LOTUS Study
Presented by: Louise Cosand
Poster sponsored by: Acadia Pharmaceuticals Inc.
Poster #10: Time to Response to Trofinetide in Patients with Rett Syndrome: Results from Trofinetide Clinical Trials
Presented by: Alyssa Peckham
Poster sponsored by: Acadia Pharmaceuticals Inc.
Poster #11: Dupilumab Treatment Reduces Medium- and High-Potency Topical Corticosteroid Usage in Pediatric Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis
Presented by: Sanofi
Poster sponsored by: Victoria Lee
Poster #12: Growth Improvement in Children 6 to 11 Years Old with Severe Atopic Dermatitis Treated with Dupilumab Irrespective of TCS Use
Presented by: Victoria Lee
Poster sponsored by: Sanofi
Poster #13: Systemic Treatments Outcomes for Moderate-to-Severe Atopic Dermatitis in Children Aged Less Than 12 Years: PEDISTAD 5-Year Results
Presented by: Sanofi
Poster sponsored by: Victoria Lee
Poster #14: Dupilumab Treatment Provides Multidimensional Benefits in Patients With Prurigo Nodularis
Presented by: Victoria Lee
Poster sponsored by: Sanofi
Poster #15: Dupilumab Reduced Itch and Urticaria Activity in Chronic Spontaneous Urticaria Patient Subpopulations
Presented by: Victoria Lee
Poster sponsored by: Sanofi
Poster #16: Dupilumab Treatment Up to 3 Years Improves Symptoms and Quality of Life Across Racial Subgroups in Infants and Children Aged 6 Months to 11 Years With Atopic Dermatitis
Presented by: Victoria Lee
Poster sponsored by: Sanofi
Poster #17: Dupilumab Maintains Long-Term Symptomatic Improvement Through 100 Weeks in Children With Eosinophilic Esophagitis, as Reported by Caregivers: Results from the Open-label Extension of the Phase 3 EoE KIDS Study
Presented by: Maherah Shaikh
Poster sponsored by: Sanofi
Poster #18: Improved Quality of Life Over 1 Year in Patients With Asthma Who Initiate Dupilumab in a Real-World Clinical Setting: The RAPID Registry
Presented by: Josiane Abou-JaoudeÂ
Poster sponsored by: Sanofi
